Update and new trends in antiemetic therapy: the continuing need for novel therapies.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Annals of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdq600PMID 20947707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aprepitant

  2012cited by this paper
• National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010.

  2011cited by this paper
• Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

  2010influential reference
• Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support

  2010cited by this paper
• Acute emesis: moderately emetogenic chemotherapy

  2010cited by this paper
• Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting.

  2010cited by this paper
• Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

  2010cited by this paper
• Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): A randomized phase III trial.

  2010cited by this paper
• Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.

  2010cited by this paper
• Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.

  2010cited by this paper
• Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

  2009cited by this paper
• Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.

  2009cited by this paper
• Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy.

  2009cited by this paper
• Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

  2009cited by this paper
• Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting.

  2009cited by this paper
• Chemotherapy-induced nausea and vomiting.

  2008cited by this paper
• Palonosetron (PALO) versus granisetron (GRAN), both combined with dexamethasone (DEX) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with cisplatin- or anthracycline plus cyclophosphamide-based regimens: Results of a phase III trial in Japanese patients

  2008cited by this paper
• Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.

  2008cited by this paper
• Effect of casopitant, a novel neurokinin -1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of steady-state warfarin

  2008cited by this paper
• Chemotherapy-Induced Nausea and Vomiting

  2008cited by this paper
• A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

  2007cited by this paper
• Comparative activity of antiemetic drugs.

  2007influential reference
• Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer

  2007cited by this paper
• Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis.

  2006cited by this paper
• A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.

  2006cited by this paper
• Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.

  2006cited by this paper
• Complete rescue from established emesis by the NK-1 receptor antagonist, casopitant mesylate, in cisplatin-induced delayed emesis in the ferret.

  2006cited by this paper
• Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

  2006cited by this paper
• Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.

  2006cited by this paper
• American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

  2006cited by this paper
• Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism

  2005cited by this paper
• Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin

  2005cited by this paper
• Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting

  2005cited by this paper
• Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

  2005cited by this paper
• Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy

  2005cited by this paper
• Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.

  2005cited by this paper
• Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

  2005cited by this paper
• Acute emesis: moderately emetogenic chemotherapy

  2005cited by this paper
• The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

  2005cited by this paper
• Model predicts age of ovarian failure in patients with cancer.

  2005cited by this paper
• Prolonged Administration of Aprepitant Does Not Increase Toxicity in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplant.

  2005cited by this paper
• The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

  2005cited by this paper
• Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity

  2004cited by this paper
• A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study

  2004cited by this paper
• Evaluation of Aprepitant for Treatment of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Autologous Stem Cell Transplantation.

  2004cited by this paper
• Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

  2003cited by this paper
• The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

  2003cited by this paper
• Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist

  2003cited by this paper
• Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

  2003cited by this paper
• Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

  2003cited by this paper
• A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis.

  2003cited by this paper
• Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

  2003cited by this paper
• Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869

  2002cited by this paper
• Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review

  2001cited by this paper
• Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation.

  2001cited by this paper
• Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.

  1999cited by this paper
• Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

  1999cited by this paper
• The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors

  1999cited by this paper
• Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro

  1999cited by this paper
• Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

  1998cited by this paper
• Ondansetron versus Methoclopramide, both combined with Dexamethasone, in the preventions of Cispltin induced delayed emesis.

  1997cited by this paper
• Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.

  1997cited by this paper
• Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.

  1997cited by this paper
• Quality of life studies in chemotherapy-induced emesis.

  1996cited by this paper
• Prolonged response to flutamide withdrawal and initiation of aminoglutethimide in a patient with metastatic prostate cancer

  1995cited by this paper
• Chemotherapy induced nausea and vomiting.

  1994cited by this paper
• Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients.

  1992cited by this paper
• Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

  1989cited by this paper
• Responses of neurons of canine area postrema to neurotransmitters and peptides

  1983cited by this paper

• Assessment of antiemetic potential of schaftoside through modulation of dopaminergic, serotonergic and muscarinic signaling pathways: in vivo and in silico investigations

  2025cites this paper
• Inhaling Peppermint Essential Oil as a Promising Complementary Therapy in the Treatment of Nausea and Vomiting

  2025cites this paper
• Efficacy of single low-dose dexamethasone with NEPA for the 168 h prevention of highly or moderately emetogenic chemotherapy

  2025cites this paper
• Effect of non-pharmacological interventions on chemotherapy induced delayed nausea and vomiting for tumors: a systematic review and Bayesian network Meta-analysis.

  2025cites this paper
• Awareness and interest in cannabis use for cancer management among cancer survivors

  2024cites this paper
• SIMPLE AND ROBUST METHOD FOR THE SYNTHESIS OF METOPIMAZINE BY UTILISING SMILE’S REARRANGEMENT. ELIMINATION OF GENOTOXIC IMPURITIES VIA DERIVATIZATION

  2024cites this paper
• Effect of ginger-partitioned moxibustion combined with ringheaded thumb-tack needle stimulation on gastrointestinal reactions of malignant tumor patients undergoing chemotherapy.

  2024cites this paper
• Review of the Use of Medicinal Cannabis Products in Palliative Care

  2024cites this paper
• Discovering different acupoint combinations of manual or electro-acupuncture to treat chemotherapy-induced nausea and vomiting based on the complex networks analysis

  2024cites this paper
• Possibilities of prevention of nausea during cytostatic therapy: literature review and clinical cases

  2023cites this paper
• Formulation and Evaluation of Sublingual Tablets of Meclizine Hydrochloride

  2023cites this paper
• GDNF family receptor alpha‐like antagonist antibody alleviates chemotherapy‐induced cachexia in melanoma‐bearing mice

  2023cites this paper
• GIP receptor agonism blocks chemotherapy-induced nausea and vomiting

  2023cites this paper
• Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.

  2023cites this paper
• Xiaobanxia decoction alleviates chemotherapy-induced nausea and vomiting by inhibiting GSDME-mediated pyroptosis.

  2023cites this paper
• Megestrol acetate dispersible tablets with a 5-HT3 receptor antagonist and dexamethasone vs. 5-HT3 receptor antagonist plus dexamethasone, can better control chemotherapy-induced nausea and vomiting: a randomized controlled study

  2022cites this paper
• Network pharmacology and GEO chip-based elucidation of mechanisms underlying the use of Yi Tieqing for prevention and treatment of postoperative nausea and vomiting

  2022cites this paper
• Emetogenicity of Chemotherapy Regimens and Recommended Prophylaxis: A Review of MASCC/ESMO Guidelines

  2022cites this paper
• Addition of metoclopramide to triple antiemetic therapy towards prevention of anthracycline-based chemotherapy-induced nausea and vomiting in breast cancer patients

  2022cites this paper
• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.

  2021cites this paper
• A Smartphone-Based Decision Support Tool for Predicting Patients at Risk of Chemotherapy-Induced Nausea and Vomiting: Retrospective Study on App Development Using Decision Tree Induction

  2021cites this paper
• Effect of transcranial direct current brain stimulation of the motor cortex on chemotherapy induced nausea and vomiting in female patients with breast cancer.

  2021cites this paper
• Metagenomics and chemotherapy‐induced nausea: A roadmap for future research

  2021cites this paper
• Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats

  2021cites this paper
• The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy.

  2021cites this paper
• Phase 3 study of palonosetron intravenous (IV) infusion versus IV bolus for chemotherapy-induced nausea and vomiting prophylaxis following highly emetogenic chemotherapy.

  2020cites this paper
• Quality by Design Approach for Development and Validation of Stability Indicating RP-HPLC Method for Fosaprepitant Dimeglumine

  2020cites this paper
• DDDT_A_270185 4085..4099

  2020influential citation
• A dynamic prediction engine to prevent chemotherapy-induced nausea and vomiting

  2020cites this paper
• [6]-Gingerol Ameliorates Cisplatin-Induced Pica by Regulating the TPH/MAO-A/SERT/5-HT/5-HT3 Receptor System in Rats

  2020cites this paper
• Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety.

  2020cites this paper
• Faecal microbiota transplantation: indications, evidence and safety

  2020cites this paper
• Antiemetic drugs: what to prescribe and when.

  2020cites this paper
• Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial

  2020cites this paper
• Prevention of chemotherapy-induced nausea and vomiting with acupuncture

  2020cites this paper
• A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches

  2020cites this paper
• GDF15 Induces Anorexia through Nausea and Emesis.

  2020cites this paper
• The prevalence and configuration of nausea in patients receiving intravenous chemotherapy in a private oncology centre in South Africa

  2019cites this paper
• Opportunities for cannabis in supportive care in cancer

  2019cites this paper
• Effect of acupoint therapies on chemotherapy-induced nausea and vomiting

  2019cites this paper
• Aspects of interest related to antiemesis in haematological patients

  2019cites this paper
• Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis

  2019cites this paper
• Supporting Clinical Decision Making in Cancer Care Delivery

  2019cites this paper
• Efficacy of Acupressure on Nausea and Vomiting in Children Undergoing Chemotherapy: A Systematic Review

  2019cites this paper
• A systematic review protocol

  2018cites this paper
• Effects of Oxaliplatin Treatment on the Myenteric Plexus Innervation and Glia in the Murine Distal Colon

  2018cites this paper
• Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study

  2018cites this paper
• Validation of Stability-Indicating Reverse Phase HPLC Method for the Determination of Related Substances in Fosaprepitant Dimeglumine Drug Substance

  2018cites this paper
• Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting

  2017cites this paper
• Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV

  2017cites this paper
• The Effectiveness of Hologram Bracelets in Reducing Chemotherapy-Induced Nausea and Vomiting Among Adult Patients With Cancer

  2017cites this paper
• Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?

  2017cites this paper
• Factors associated with the use of potentially inappropriate medications by older adults with cancer.

  2017cites this paper
• Deterioro cognitivo inducido por la quimioterapia en pacientes diagnosticadas de cancer de mama

  2017cites this paper
• The Effects of Dokhwaljihwang-tang Intravenous Pharmacopuncture on Cisplatin-Induced Emesis and Gastrointestinal Mobility Disorder in Rats

  2017cites this paper
• Olanzapine combined with standard antiemetic regimens for prevention of chemotherapy therapy-induced nausea and vomiting: a single-center experience from south India.

  2017influential citation
• Cancer Drug Delivery: Pharmacogenetics, Biomarkers, and Targeted Therapies

  2017cites this paper
• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis

  2017cites this paper
• Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting.

  2017cites this paper
• Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk

  2017cites this paper
• Delayed Nausea/Emesis

  2016cites this paper
• Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens

  2016cites this paper
• Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens

  2016cites this paper
• NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron

  2016cites this paper
• Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting

  2016cites this paper
• Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison

  2016cites this paper
• Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy‐Induced Nausea and Vomiting

  2016influential citation
• Varubi (Rolapitant) Approved for the Prevention of Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

  2016cites this paper
• Treating Nephroblastoma in Rwanda C. Shyirambere et al Treatment of Chronic Myeloid Leukemia in Rural Rwanda N. Tapela et al Pulmonary Nodules in Patients With Nonpulmonary Cancer

  2016cites this paper
• A novel and dynamic prediction engine for practicing precision medicine to prevent chemotherapy-induced nausea and vomiting

  2015cites this paper
• Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).

  2015cites this paper
• Supportive Care in Older Patients with Hematological Malignancies

  2015cites this paper
• In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant.

  2015cites this paper
• Pharmacogenetics of chemotherapy-induced nausea and vomiting.

  2015cites this paper
• A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

  2015cites this paper
• Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.

  2015cites this paper
• Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

  2015cites this paper
• Biological and Pharmacological Aspects of the NK1-Receptor

  2015cites this paper
• Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity.

  2015cites this paper
• An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries

  2015cites this paper
• Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin

  2015cites this paper
• Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy

  2015cites this paper
• Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)

  2015cites this paper
• Role of Psychosocial Variables on Chemotherapy-Induced Nausea and Vomiting and Health-Related Quality of Life among Cancer Patients: A European Study

  2015cites this paper
• Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open‐label, crossover phase 1 study

  2015cites this paper
• Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting

  2015cites this paper
• Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

  2015cites this paper
• Investigation of Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy

  2014cites this paper
• Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.

  2014cites this paper
• A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

  2014influential citation
• EFFECT OF 5-HT3 ANTAGONIST WITH CORTICOSTEROID IN THE TREATMENT OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

  2014cites this paper
• CORRELATION BETWEEN SMOKING, SMOKELESS TOBACCO AND ALCOHOL DRINKING AND EMESIS IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY

  2014cites this paper
• Commonly used gastrointestinal drugs.

  2014influential citation
• Physico-Chemical Stability of Mixtures of Fosaprepitant used in Clinical Practice

  2014cites this paper
• Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron

  2014cites this paper
• Anticipatory nausea and vomiting due to chemotherapy.

  2014cites this paper
• Neuropharmacology and Management of Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer

  2014cites this paper
• Droperidol for treatment of nausea and vomiting in palliative care patients.

  2014cites this paper
• Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting

  2014cites this paper
• Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

  2014influential citation